Ebronucimab vs Tafolecimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline

Ebronucimab

Marketed by Hubei Jumpcan Pharmaceutical and partners

Phase 3 in Atherosclerotic Cardiovascular Diseasemonoclonal antibody
Partial signal

NCT05255094 · Phase 3 · completed

The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 464 participants, providing a strong experimental design. Its primary endpoint was a laboratory lipid measure rather than a hard clinical outcome. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source.

Reported efficacy

Percentage change from baseline of serum LDL-C level (At week 12): LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001). (met)

Result source: NCT05255094

Tafolecimab · Sintbilo

Marketed by Innovent Biologics

Phase 3 in Atherosclerotic Cardiovascular Diseasemonoclonal antibody
Reliable signal

NCT04289285 · Phase 3 · completed

This randomised, quadruple-blind, placebo-controlled trial randomised 618 Chinese patients with non-familial hypercholesterolaemia (614 dosed) and met its primary endpoint: LDL cholesterol fell 57 to 65 percentage points more than with placebo at week 48 across both dosing regimens, a highly statistically significant result.

618 patients were randomised (publication); the registry's actual-enrolment field says 804.

Next expected readout: December 2026 · NCT07341958 (registry estimate)

Reported efficacy

Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at week 48: LDL-C percent change from baseline to week 48, treatment difference vs placebo: -65.0% (97.5% CI: -70.2%, -59.9%) for tafolecimab 450 mg Q4W; -57.3% (97.5% CI: -64.0%, -50.7%) for 600 mg Q6W; both P < 0.0001 (met)

Result source: NCT04289285

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEbronucimabTafolecimab
LDL-C, % change—Not posted · NCT05260411-58.7% vs 3.2%a−61.9 vs placebotafolecimab 450mg Q4W · wk 12NCT04179669
2 other results
  • -58.4% vs -1% tafolecimab 150mg Q2W · wk 12 · Phase 3 · primary NCT04179669
  • -68.9% vs -5.8% wk 12 · Phase 3 · primary NCT04709536
Non-HDL-C, % change—Not posted · NCT05260411—Not posted · NCT04031742
ApoB, % change—Not posted · NCT05260411—Not posted · NCT04031742
Lp(a), % change—Not posted · NCT05260411—Not posted · NCT04031742
3-point MACE (% with event)—Not posted · NCT05260411—Not posted · NCT04031742

LDL-C, % change

Ebronucimab
—Not posted · NCT05260411
Tafolecimab
-58.7% vs 3.2%a−61.9 vs placebotafolecimab 450mg Q4W · wk 12NCT04179669
2 other results
  • -58.4% vs -1% tafolecimab 150mg Q2W · wk 12 · Phase 3 · primary NCT04179669
  • -68.9% vs -5.8% wk 12 · Phase 3 · primary NCT04709536

Non-HDL-C, % change

Ebronucimab
—Not posted · NCT05260411
Tafolecimab
—Not posted · NCT04031742

ApoB, % change

Ebronucimab
—Not posted · NCT05260411
Tafolecimab
—Not posted · NCT04031742

Lp(a), % change

Ebronucimab
—Not posted · NCT05260411
Tafolecimab
—Not posted · NCT04031742

3-point MACE (% with event)

Ebronucimab
—Not posted · NCT05260411
Tafolecimab
—Not posted · NCT04031742
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ebronucimab

LDL-C -59.13% @ 12wk450 mg Q4W
percent change · % of baseline
No placebo or comparator arm
NCT05255094 · Phase 3 · sponsor-reported, not registry data
show 1 more result
-60.43% @ 12wk150 mg Q2W
NCT05255094 · Phase 3 · sponsor-reported, not registry data

Tafolecimab

LDL-C -58.7% vs 3.2% placebo @ 12wktafolecimab 450mg Q4W
percent change · % of baseline
NCT04179669 · Phase 3 · sponsor-reported, not registry data
show 2 more results
-58.4% vs -1% placebo @ 12wktafolecimab 150mg Q2W
NCT04179669 · Phase 3 · sponsor-reported, not registry data
-68.9% vs -5.8% placebo @ 12wk
NCT04709536 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ebronucimab's landscape · Tafolecimab's landscape